FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a therapeutic and preventive drug for treating osteoarthritis and arthritis (synovitis) accompanying osteoarthritis.
EFFECT: using the anti-Fas IgM antibody ensures the elimination of osteoarthritis symptoms, since using the anti-Fas IgM antibodies can inhibiting the production of an enzyme destroying the cartilage matrix, as using the anti-Fas IgM antibodies can increase the production of the cartilage matrix.
3 cl, 52 dwg, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR DIAGNOSTICS OF OSTEOARTHRITIS AT CAT FAMILY | 2008 |
|
RU2504586C2 |
| APPLICATION OF SOPHORICOSIDE FOR PREPARING DRUGS | 2009 |
|
RU2454236C1 |
| APPLICATION OF PAK INHIBITOR FOR ARTHROPATHY TREATMENT | 2004 |
|
RU2360696C2 |
| SCHEME FOR USING FGF-18 COMPOUND | 2015 |
|
RU2700582C2 |
| METHOD FOR APPLYING ANNEALED PYRROLE COMPOUNDS WHEN TREATING ARTICULAR CARTILAGE DEGENERATION OR STRUCTURAL SUBCHONDRAL BONE TRANSFORMATIONS | 2002 |
|
RU2303447C2 |
| IMPLANT CONTAINING FGF-18 | 2015 |
|
RU2700414C2 |
| SCHEME FOR USING FGF-18 COMPOUND | 2015 |
|
RU2691946C2 |
| APPLICATION OF FUSED TIMP-GPI CONSTRUCT AND METHOD OF TREATING SKIN INJURES FOR CICATRISATION PREVENTION OR INHIBITION | 2006 |
|
RU2428479C2 |
| RECOMBINANT MOLECULES OF LUBRICIN AND THEIR USE | 2004 |
|
RU2376313C2 |
| FGF-18 IN TRANSPLANTATION AND TISSUE ENGINEERING PROCEDURES | 2015 |
|
RU2682159C2 |
